Follow
Ruolin Lu
Ruolin Lu
Senior Scientist, Pfizer
Verified email at pfizer.com
Title
Cited by
Cited by
Year
Sweet berberine
C Wang, SR Perumalla, R Lu, J Fang, CC Sun
Crystal Growth & Design 16 (2), 933-939, 2016
662016
Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator
R Lu, C Groer, PA Kleindl, KR Moulder, A Huang, JR Hunt, S Cai, ...
Journal of controlled release 306, 165-176, 2019
582019
Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials
A Huang, MM Pressnall, R Lu, SG Huayamares, JD Griffin, C Groer, ...
Journal of controlled release 326, 203-221, 2020
362020
Intratumoral cancer chemotherapy with a carrier-based immunogenic cell-death eliciting platinum (IV) Agent
C Groer, T Zhang, R Lu, S Cai, D Mull, A Huang, M Forrest, C Berkland, ...
Molecular pharmaceutics 17 (11), 4334-4345, 2020
162020
Glatiramer Acetate Complexed with CpG as Intratumoral Immunotherapy in Combination with Anti-PD-1
A Huang, C Groer, R Lu, ML Forrest, JD Griffin, CJ Berkland
Molecular Pharmaceutics 19 (11), 4357-4369, 2022
22022
Platinum (IV) conjugates and methods of use
L Forrest, D Aires, R Moulder, R Lu, J Hunt, P Kleindl, T Zhang, C Groer, ...
US Patent 11,458,163, 2022
2022
Imidazoquinoline compounds and prodrugs thereof
L Forrest, D Aires, R Moulder, R Lu, J Hunt, P Kleindl, T Zhang, C Groer, ...
US Patent App. 17/598,160, 2022
2022
Design and Delivery of TLR7/8 Agonists for Immunotherapy
R Lu
University of Kansas, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–8